<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04316065</url>
  </required_header>
  <id_info>
    <org_study_id>YHP1906-101</org_study_id>
    <nct_id>NCT04316065</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study Between YHP1906 Tab. 5 mg and YHR1902 Tab. 5 mg</brief_title>
  <official_title>A Randomized, Open-label, Single-dose, 2-sequence, 2-period, Crossover Clinical Trial to Investigate the Bioequivalence Between YHP1906 Tab. 5 mg and YHR1902 Tab. 5 mg in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Metro Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, open-label, single-dose, 2-sequence, 2-period, crossover clinical trial to
      investigate the bioequivalence between YHP1906 Tab. 5 mg and YHR1902 Tab. 5mg in healthy
      volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      30 healthy subjects will be randomized to one of the 2 groups in the same ratio.

      Subjects in group 1 will be administered &quot;comparator&quot; and &quot;YHP1906 Tab. 5 mg&quot; by cross-over
      design on day 1, 8.

      Subjects in group 2 will be administered &quot;YHP1906 Tab. 5 mg&quot; and &quot;comparator&quot; by cross-over
      design on day 1, 8
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 11, 2020</start_date>
  <completion_date type="Actual">April 24, 2020</completion_date>
  <primary_completion_date type="Actual">April 20, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma drug concentration-time curve [AUCt]</measure>
    <time_frame>0-36 hours</time_frame>
    <description>Area under the plasma drug concentration-time curve [AUCt] of Apixaban</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration [Cmax]</measure>
    <time_frame>0-36 hours</time_frame>
    <description>Maximum plasma concentration [Cmax] of Apixaban</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma drug concentration-time curve from time 0 to infinity [AUCinf]</measure>
    <time_frame>0-36 hours</time_frame>
    <description>Area under the plasma drug concentration-time curve from time 0 to infinity [AUCinf] of Apixaban</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma drug concentration-time curve/Area under the plasma drug concentration-time curve from time 0 to infinity [AUCt/AUCinf]</measure>
    <time_frame>0-36 hours</time_frame>
    <description>Area under the plasma drug concentration-time curve/Area under the plasma drug concentration-time curve from time 0 to infinity [AUCt/AUCinf] of Apixaban</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of peak concentration [Tmax]</measure>
    <time_frame>0-36 hours</time_frame>
    <description>Time of peak concentration [Tmax] of Apixaban</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal phase of half-life [t1/2]</measure>
    <time_frame>0-36 hours</time_frame>
    <description>Terminal phase of half-life [t1/2] of Apixaban</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>15 subjects, Cross-over, Single dose of comparator on day 1, Single dose of YHP1906 on day 8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>15 subjects, Cross-over, Single dose of YHP1906 on day 1, Single dose of comparator on day 8</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YHP1906</intervention_name>
    <description>YHP1906 Tab. 5 mg</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YHR1902</intervention_name>
    <description>Comparator. YHR1902 Tab. 5 mg</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adults aged 19 and above with body mass index(BMI) between 18.5 and 30.0 kg/m2

          2. Acceptable medical history, physical examination and laboratory tests during screening

          3. Subjects who has signed a written informed consent voluntarily, prior to any
             procedure, using a form that is approved by the local Institutional Review Board after
             detailed explanation of the purpose, contents, and characteristic of the drug

        Exclusion Criteria:

          1. History of clinically significant disease

          2. Administration of ETC(ethical-the-counter drug) within 2 weeks or OTC(over-the-counter
             drug) within 1 week prior to the first dosing

          3. Have AST(GOT) and/or ALT(GPT) and/or GGT(Î³GT) and/or Total Bilirubin &gt; 1.5 times of
             normal upper limit

          4. Volunteers considered not eligible for the clinical trial by the investigator

          5. Administration of other investigational products within 6 months prior to the first
             dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sungdae Kwon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Metro Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Metro Hospital</name>
      <address>
        <city>Anyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>14096</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 18, 2020</study_first_submitted>
  <study_first_submitted_qc>March 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2020</study_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Bioequivalence</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

